

Clinical Pathway Board Meeting 20th September 2017

Paper 1 – Minutes of the Board meeting held on 29th June May 2017

Presented by Satish Maddineni

Actions for the Board

1. The board to approve the record

Urology Pathway Board Meeting

Minutes of the meeting held on
29th June 2017

Members in attendance

Satish Maddineni (Chair)	Pathway Director	Noel Clarke	Consultant Surgeon
Mike Thorpe	User representative	Rose Garvey	User representative
Stephen Bromage	Consultant Surgeon	Dan Burke	Consultant Surgeon
Jeremy Oates	Consultant Surgeon	Hazel Warburton	Consultant Surgeon
Jacob Cherian	Consultant Surgeon	Jacob Cherian	Consultant Surgeon
George Yeung	Consultant Radiologist		

In attendance

James Leighton	GM Cancer	Sarah Darley	Respect 21 project
Natasha Smith	GMC MCUI		

1. Welcome and introductions

SM welcomed all to the meeting and noted the apologies received.

2. Minutes of the last meeting

These were accepted as a true record and there were no matters arising.

3. Urology aftercare pathways update

Discussion summary	SM confirmed that the aftercare pathway steering group had adopted the pathways as designed. He confirmed that this would not be moving to a pilot phase to test.
Conclusion	The Board noted this report.
Actions & responsibility	There were no actions for the Board following this discussion.

4. The Greater Manchester Cancer plan**4.1 62 day delivery**

Discussion summary	The Board reviewed the tabled report on the 62 day performance in Urology. Whilst the board found this useful they felt that it needed to be broken down by provider and tumour type to help improve future reviews.
Conclusion	The Board noted this report and asked for the detail to be provided.
Actions & responsibility	JL to meet with data analysts and add the required data to future reports

4.2 Guideline update

Discussion summary	JO updated the group on the progress of the Bladder guidelines. SB confirmed he has started a review of the nephron sparing guidelines. NWC agreed to review the prostate guidelines. JO agreed to review the bladder guidelines. DB & SB agreed to review the renal guidelines.
Conclusion	The Board noted this discussion.
Actions & responsibility	Nominated Board members to progress each relevant review. All nominated reviewers to refresh the relevant guideline.

4.3 Recovery Package

Discussion summary	SM outlined the expectations of the Board in delivering the recovery package. He explained that <u>End of treatment summaries</u> – HJ to lead on this in collaboration with the CNS group <u>Health & Well-being events</u> – HJ was scoping what was currently happening and reporting back to the Board HW advised the Board that UHSM had already developed a document and was willing to share.
Conclusion	The Board noted this discussion and asked for this to be added to the next meeting agenda
Actions & responsibility	HJ to report to the next meeting on draft end of treatment summaries and the current provision of Health & Well-being events in GM.

4.4 Board education event

Discussion summary	SM outlined that the Board were expected to organise an education event each year and that one needs to be organised in this year. He proposed that it should be again aimed at GPs and be held on a Saturday Morning.
Conclusion	The Board agreed to support organising this event
Actions & responsibility	JL to develop a proposal and bring it back to the next meeting of the group.

4.5 GM Policy on template biopsies

Discussion summary	This item was addressed as part of the discussion on the National Best Timed Prostate Pathway project
--------------------	---

4.6 Review of MDT Structures & processes


Discussion summary	SM explained that this was an important element of the service transformation and the views of the Board would be pertinent to this. He asked that Board members take a lead to review current MDT structures and outline possible model of future MDT provision. He advised that it would be useful to have the number of referrals to each MDT.
Conclusion	
Actions & responsibility	JL to develop a report on MDT volumes and circulate to reviewers JO – to take a lead on reviewing Bladder MDT discussions NWC – to take a lead on reviewing Prostate MDT discussions SB - to take a lead on reviewing Renal MDT discussions

5. Board projects updates

5.1 Jansen Project

Discussion summary	JL updated the group on the progress of this project. He explained that there with access to data from Pennine and he hoped that this was now resolved. It is anticipated that this project will commence shortly.
Conclusion	The Board noted this discussion.
Actions & responsibility	There were no actions for the Board following this discussion.

5.2 Active surveillance audit

Discussion summary	SB provided the board with a report on the initial findings of this audit and the Board had a wide ranging discussion on the findings. His presentation is embedded below for information.  Active surveillance audit pathway board.
Conclusion	The Board noted this discussion.
Actions & responsibility	There were no actions for the Board following this discussion.

6. Transformation update

Discussion summary	DB provided the Board with a report of the first meeting of the Urology implementation group which took place on the 28 th June. He explained that he understood the formal announcement was to be made in the near future. He went onto explain that the transformation would be undertaken in a phased approach and would run alongside the transformation of the benign provision model.
Conclusion	The Board noted this discussion.
Actions & responsibility	There were no actions for the Board following this discussion.

7. Research update

Discussion summary	In TE's absence this item was deferred until the next meeting.
--------------------	--

8. National Best Timed Prostate Pathway –update

Discussion summary	<p>SM provided an update on this project explaining that GM was leading on this national project in collaboration with London Vanguard partner organisations.</p> <p>He outlined the work completed so far and spoke to the tabled documents of pre-referral and treatment phases of the pathway. The Board had a wide ranging discussion on these drafts and agreed to keep it under review as the project develops.</p> <p>The Board also discussed the impact on the provision of Template biopsies in GM.</p>
Conclusion	The Board noted this discussion and asked to be updated as the work progresses.
Actions & responsibility	There were no actions for the Board following this discussion.

9. User involvement update

Discussion summary	As NS had just started with the UI team, MT provided the update. He explained that recruitment to the vacant UI posts had been completed and that the team should be back at full strength in the next few weeks.
Conclusion	The Board noted this discussion.
Actions & responsibility	There were no actions for the Board following this discussion.

10. Any other business

Discussion summary	HW brought up an issue about GP prescribing...not sure what??
Conclusion	
Actions & responsibility	

Date and time of meeting **Wednesday 20th September, 14.00 – 16.00hrs SRFT**

Date and time of meeting in 2017

Tuesday 14th November